Who are Androgen Suppression Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Short term androgen deprivation, Long term androgen deprivation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/androgen-suppression-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Androgen Suppression Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Androgen Suppression Therapy (Androgen Suppression Therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen deprivation therapy (ADT). Area: Oncology.

phase 3 Androgen deprivation therapy (ADT) Androgen receptor pathway / testosterone / DHT Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Androgen Suppression Therapy (Androgen Suppression Therapy) — Proton Collaborative Group. Androgen suppression therapy reduces circulating testosterone and DHT levels to inhibit androgen-dependent cancer cell growth.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Androgen Suppression Therapy TARGET	Androgen Suppression Therapy	Proton Collaborative Group	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor pathway / testosterone / DHT
Short term androgen deprivation	Short term androgen deprivation	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor / testosterone production
Long term androgen deprivation	Long term androgen deprivation	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen deprivation therapy (ADT) class)

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · 2 drugs in this class
Proton Collaborative Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Androgen Suppression Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/androgen-suppression-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing